GYRE
Gyre Therapeutics, Inc.7.58
+0.04+0.53%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
730.21MP/E (TTM)
189.50Basic EPS (TTM)
0.04Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Hydronidone Phase 3 success
Gyre Therapeutics released an updated corporate presentation on September 10, 2025, highlighting positive Phase 3 topline results for Hydronidone in CHB-associated liver fibrosis. The trial met its primary endpoint with 52.85% of patients achieving ≥1-stage fibrosis regression versus 29.84% on placebo (P=0.0002), alongside favorable safety showing no discontinuations due to adverse events. This positions Hydronidone for NDA filing with China's NMPA in Q3 2025 and U.S. IND in 2025. Hydronidone advances fibrosis reversal.
8-K
Gyre appoints seasoned CRO expert
Gyre Therapeutics appointed Dan Weng, M.D., as a Class II director effective August 18, 2025, nominated by parent GNI Group Ltd. Dr. Weng brings four decades of CRO leadership, including growth at Medelis and EPS in Asia, plus regulatory expertise from Harvard and global trials. His insights will aid Gyre's pipeline expansion, like Hydronidone's Q3 2025 NDA filing. No related transactions disclosed.
10-Q
Q2 FY2025 results
Gyre Therapeutics posted Q2 revenue of $26.8 million, up 6% year-over-year but down from $22.1 million in Q1 (derived), thanks to launches of Etorel and Contiva offsetting a dip in ETUARY sales amid tougher competition in China's IPF market. Operating income fell to $2.2 million from $3.2 million last year, with gross margins holding steady at 95.7% despite higher costs from new products; diluted EPS came in at $0.00 on 102.7 million shares, reflecting anti-dilution from warrants. Cash climbed to $36.5 million after a $23 million public offering, while free cash flow turned positive at $1.6 million (derived from $2.0 million operating cash minus $0.4 million capex). Etorel's June debut added $1.6 million in sales, recognizing $4.9 million technology rights amortized over 7.4 years. New products are gaining traction. Yet competition from generics pressures ETUARY volumes.
ATYR
aTyr Pharma, Inc.
0.73-0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
FGEN
FibroGen, Inc
9.51-0.53
GLTO
Galecto, Inc.
30.00-1.60
GOSS
Gossamer Bio, Inc.
3.56-0.23
GRI
GRI Bio, Inc.
0.48+0.00
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
RNTX
Rein Therapeutics, Inc.
1.35-0.13
SYRE
Spyre Therapeutics, Inc.
32.97-0.37